hVIVO (OPORF) Cash Flow from Others: $0.76 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OPORF hVIVO PLC OPORF
48 GF Score
Price $0.11
GF Value $0.27
! 6 Warning Signs
View Full Analysis

What is hVIVO Cash Flow from Others?

hVIVO OPORF +27.29% 48 Cash Flow from Others is $0.76 Mil as of Dec. 2025. GuruFocus rates OPORF with a GF Score™ of 48/100 and a GF Value™ of $0.27. The stock has 6 warning signs investors should review.

hVIVO's cash flow from others for the six months ended in Dec. 2025 was $-1.53 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2025 was $0.76 Mil.

hVIVO Cash Flow from Others Related Terms

hVIVO Cash Flow from Others Historical Data

* Premium members only.

The historical data trend for hVIVO's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

hVIVO Cash Flow from Others Chart

hVIVO Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Others
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 8.42 -0.31 -2.34 0.75

hVIVO Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 -1.11 -1.25 2.29 -1.53
OPORF
48GF Score
hVIVO PLC OPORF
Cash Flow from Others is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

hVIVO Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.76 Mil.

Frequently Asked Questions Learn more about Cash Flow from Others →
What does a Cash Flow from Others of $0.76 Mil mean?
hVIVO (OPORF) has a Cash Flow from Others of $0.76 Mil as of Dec. 2025. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for hVIVO and its competitors.
Is hVIVO's Cash Flow from Others too high?
hVIVO's current Cash Flow from Others is $0.76 Mil. Overall, hVIVO has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does hVIVO's Cash Flow from Others compare to TMO and DHR?
hVIVO's Cash Flow from Others of $0.76 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Others for a Medical Diagnostics & Research company?
A good Cash Flow from Others depends on the Medical Diagnostics & Research industry context. However, Cash Flow from Others should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Others mean?
A high Cash Flow from Others can signal that a stock is expensive relative to its fundamentals. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for hVIVO and its competitors. hVIVO's current Cash Flow from Others is $0.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
hVIVO (OPORF) has a current Cash Flow from Others of $0.76 Mil. The stock's GF Value™ is $0.27, compared to a current price of $0.11 — trading 59.4% below its estimated fair value. The current Cash Flow from Others is $0.76 Mil. hVIVO's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Others calculated?
Cash Flow from Others is calculated from a company's financial statements. For hVIVO (OPORF), the current Cash Flow from Others is $0.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is hVIVO (OPORF) Overvalued in 2026?

Based on GuruFocus' analysis, hVIVO stock appears to be undervalued. The current stock price of $0.11 is trading 59.4% below its estimated GF Value™ of $0.27.

Key valuation signals for OPORF:

  • Cash Flow from Others: $0.76 Mil
  • GF Value™: $0.27 vs. price of $0.11 (59.4% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

hVIVO Business Description

Other Exchanges HVO:UKCRO:Germany
Address 40 Bank Street, Floor 24, London, GBR, E14 5NR
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
48GF Score

Get the complete analysis for OPORF

Cash Flow from Others is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.27
GF Value